CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Rochester, Minnesota, United States and 15 other locations
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorect ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 7 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Rochester, Minnesota, United States and 59 other locations
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON...
Phase 1, Phase 2
Rochester, Minnesota, United States and 29 other locations
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorec ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 10 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Rochester, Minnesota, United States and 65 other locations
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic acti...
Phase 1, Phase 2
Rochester, Minnesota, United States and 11 other locations
(PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors...
Phase 1
Rochester, Minnesota, United States and 15 other locations
to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors...
Phase 2
Rochester, Minnesota, United States and 63 other locations
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with adv...
Phase 1
Rochester, Minnesota, United States and 22 other locations
Clinical trials
Research sites
Resources
Legal